Numerous New Targets, Increased Use of Drugs in Combination, and Premium Pricing are Contributors to the Enormous Sales Potential of Novel Cancer Therapies Entering the Market Over the Next 15 Years
14th Nov 2006, 16:24 GMT
Combined, Five New Classes of Cancer Drugs Will Exceed $20 Billion in Sales in 2021, According to a New Report from Decision Resources
Numerous New Targets, Increased Use of Drugs in Combination, and Premium Pricing are Contributors to the Enormous Sales Potential of Novel Cancer Therapies Entering the Market Over the Next 15 Years related news:
- Emerging Cancer Vaccine Market Poised to Surpass $8 Billion by 2012 — PR Leap - Health News Releases
- New drug comb may lengthen ovarian cancer survival — Reuters: Health
- Targeted cancer drugs may work by disrupting balance of cellular signals — EurekAlert! - Cancer
- Childhood Cancer Survivors Treated With Radiation Face Increased Risk Of Tumors Later In Life — ScienceDaily Headlines
- Spectra Premium Industries Inc.: Privatization Proposed to Spectra Premium Shareholders — Market Wire - Automotive
- Gladstone and Merck team to bring drugs to market — bizjournals.com Health Care:Pharmaceuticals headlines
- Taiwan market: Telecom carriers object to NCC draft pricing control scheme — DigiTimes: IT news from Asia
- LCD TV Shipments Double Year-Over-Year — 1080eye: Mark Kersey's HDTV News Blog
- U-M researchers use nanoparticles to target brain cancer — EurekAlert! - Cancer
- Novel Vaccine Shows Promise Against Early-stage Breast Cancer — ScienceDaily Headlines
Latest news from Partnerships/ Joint Ventures News from StratCenter.com:
- Local firm forms foundation for women's sexual health
- Lifeline Therapeutics to Recognize Previously Deferred Retail Chain Revenue
- Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the American College of Rheumatology Meeting
- NextGen Healthcare and Primetime Medical Software Partner to Enhance Communications Between Doctors and Patients
- 3 Keane Executives to Present at the 2006 Gartner Healthcare Summit in San Diego
- Yaupon Therapeutics Closes $4 mln Financing
- CareTech Solutions and Yampa Valley Med Cntr Announce New IT Outsourcing Agreement
- Genelabs Technologies Reports Financial Results for Q3 and 1st 9 Months of 2006
- Frost & Sullivan Honors Covance for Superior Market Leadership, Creating Enhanced Customer Value in the North American CRO Market
- Health Care Property Closes $1B Offering